# JBT MAREL Corp: financial statements, quarterly

JBTM · NYSE · CIK 1433660 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/jbtm.md) · [Financials](/companies/jbtm/financials.md) · [Filings](/companies/jbtm/filings.md) · [Insiders](/companies/jbtm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/jbtm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [454](/filings/0001433660-25-000065.md) | [445](/filings/0001433660-24-000008.md) | [392](/filings/0001433660-25-000026.md) | [421](/filings/0001628280-26-053548.md) | [454](/filings/0001433660-25-000065.md) | [468 d](/filings/0001433660-26-000053.md) | [854](/filings/0001628280-26-030756.md) | [935](/filings/0001628280-26-053548.md) | [1,001](/filings/0001433660-25-000065.md) | [1,008 d](/filings/0001433660-26-000053.md) | [936](/filings/0001628280-26-030756.md) | [981](/filings/0001628280-26-053548.md) |
| Cost of revenue | $m | [259](/filings/0001433660-24-000008.md) | [284](/filings/0001433660-24-000008.md) | [252](/filings/0001433660-25-000026.md) | [259](/filings/0001433660-25-000045.md) | [290](/filings/0001433660-25-000065.md) | [288 d](/filings/0001433660-26-000053.md) | [562](/filings/0001628280-26-030756.md) | [600](/filings/0001628280-26-053548.md) | [642](/filings/0001433660-25-000065.md) | [660 d](/filings/0001433660-26-000053.md) | [607](/filings/0001628280-26-030756.md) | [622](/filings/0001628280-26-053548.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | [6.4](/filings/0001433660-25-000026.md) | [5.8](/filings/0001433660-25-000045.md) | [5.4](/filings/0001433660-25-000065.md) | [3.3 d](/filings/0001433660-26-000053.md) | [33.6](/filings/0001433660-25-000026.md) | [30.9](/filings/0001433660-25-000045.md) | [28.7](/filings/0001433660-25-000065.md) | [23.1 d](/filings/0001433660-26-000053.md) | not reported | not reported |
| Selling, general and administrative | $m | [102](/filings/0001433660-24-000048.md) | [104 d](/filings/0001433660-24-000008.md) | [104](/filings/0001433660-25-000026.md) | [110](/filings/0001433660-25-000045.md) | [112](/filings/0001433660-25-000065.md) | not reported | [325](/filings/0001628280-26-030756.md) | [287](/filings/0001628280-26-053548.md) | [222](/filings/0001433660-25-000065.md) | not reported | [261](/filings/0001628280-26-030756.md) | [313](/filings/0001628280-26-053548.md) |
| Operating income | $m | [36.9](/filings/0001433660-24-000048.md) | [55.1 d](/filings/0001433660-26-000053.md) | [29.1](/filings/0001433660-25-000026.md) | [26.8](/filings/0001433660-25-000045.md) | [46.8](/filings/0001433660-25-000065.md) | [15.7 d](/filings/0001433660-26-000053.md) | [(33.0)](/filings/0001628280-26-030756.md) | [48.0](/filings/0001628280-26-053548.md) | [102](/filings/0001433660-25-000065.md) | [72.3 d](/filings/0001433660-26-000053.md) | [68.0](/filings/0001628280-26-030756.md) | [46.0](/filings/0001628280-26-053548.md) |
| Interest expense | $m | [5.5](/filings/0001433660-24-000048.md) | [3.1 d](/filings/0001433660-26-000053.md) | [2.9](/filings/0001433660-25-000026.md) | [4.1](/filings/0001433660-25-000045.md) | [4.1](/filings/0001433660-25-000065.md) | [8.3 d](/filings/0001433660-26-000053.md) | [42.4](/filings/0001433660-25-000026.md) | [31.8](/filings/0001433660-25-000045.md) | [24.7](/filings/0001433660-25-000065.md) | [15.5 d](/filings/0001433660-26-000053.md) | not reported | [13.0](/filings/0001628280-26-053548.md) |
| Income tax | $m | [4.6](/filings/0001433660-24-000048.md) | [5.7 d](/filings/0001433660-26-000053.md) | [8.1](/filings/0001433660-25-000026.md) | [(3.3)](/filings/0001433660-25-000045.md) | [9.5](/filings/0001433660-25-000065.md) | [(3.6) d](/filings/0001433660-26-000053.md) | [(46.0)](/filings/0001628280-26-030756.md) | [8.0](/filings/0001628280-26-053548.md) | [17.1](/filings/0001433660-25-000065.md) | [8.1 d](/filings/0001433660-26-000053.md) | [15.0](/filings/0001628280-26-030756.md) | [7.0](/filings/0001628280-26-053548.md) |
| Net income | $m | [442](/filings/0001433660-24-000048.md) | [81.1](/filings/0001433660-24-000008.md) | [22.8](/filings/0001433660-25-000026.md) | [30.7](/filings/0001433660-25-000045.md) | [38.9](/filings/0001433660-25-000065.md) | [(7.0) d](/filings/0001433660-26-000053.md) | [(173)](/filings/0001628280-26-030756.md) | [3.0](/filings/0001628280-26-053548.md) | [66.0](/filings/0001433660-25-000065.md) | [53.1 d](/filings/0001433660-26-000053.md) | [45.0](/filings/0001628280-26-030756.md) | [28.0](/filings/0001628280-26-053548.md) |
| Diluted EPS | $ per share | [13.73](/filings/0001433660-24-000048.md) | [2.52](/filings/0001433660-24-000008.md) | [0.71](/filings/0001433660-25-000026.md) | [0.95](/filings/0001433660-25-000045.md) | [1.21](/filings/0001433660-25-000065.md) | not reported | [(3.35)](/filings/0001628280-26-030756.md) | [0.07](/filings/0001628280-26-053548.md) | [1.26](/filings/0001433660-25-000065.md) | not reported | [0.86](/filings/0001628280-26-030756.md) | [0.54](/filings/0001628280-26-053548.md) |
| Basic EPS | $ per share | [13.79](/filings/0001433660-24-000048.md) | [2.54](/filings/0001433660-24-000008.md) | [0.71](/filings/0001433660-25-000026.md) | [0.96](/filings/0001433660-25-000045.md) | [1.22](/filings/0001433660-25-000065.md) | not reported | [(3.35)](/filings/0001628280-26-030756.md) | [0.07](/filings/0001628280-26-053548.md) | [1.26](/filings/0001433660-25-000065.md) | not reported | [0.86](/filings/0001628280-26-030756.md) | [0.54](/filings/0001628280-26-053548.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [483](/filings/0001433660-26-000053.md) | not reported | not reported | not reported | [1,228](/filings/0001433660-26-000053.md) | not reported | not reported | not reported | [168](/filings/0001433660-26-000053.md) | not reported | not reported |
| Current assets | $m | [1,092](/filings/0001433660-23-000041.md) | [1,100](/filings/0001433660-25-000009.md) | [1,102](/filings/0001433660-24-000020.md) | [1,125](/filings/0001433660-24-000035.md) | [1,206](/filings/0001433660-24-000048.md) | [1,863](/filings/0001433660-26-000053.md) | [1,489](/filings/0001433660-25-000026.md) | [1,529](/filings/0001433660-25-000045.md) | [1,540](/filings/0001433660-25-000065.md) | [1,583](/filings/0001628280-26-053548.md) | [1,675](/filings/0001628280-26-030756.md) | [1,614](/filings/0001628280-26-053548.md) |
| Total assets | $m | [2,689](/filings/0001433660-23-000041.md) | [2,710](/filings/0001433660-25-000009.md) | [2,691](/filings/0001433660-24-000020.md) | [2,690](/filings/0001433660-24-000035.md) | [2,789](/filings/0001433660-24-000048.md) | [3,414](/filings/0001433660-26-000053.md) | [7,999](/filings/0001433660-25-000026.md) | [8,253](/filings/0001433660-25-000045.md) | [8,199](/filings/0001433660-25-000065.md) | [8,191](/filings/0001628280-26-053548.md) | [8,163](/filings/0001628280-26-030756.md) | [8,006](/filings/0001628280-26-053548.md) |
| Current liabilities | $m | [584](/filings/0001433660-23-000041.md) | [484](/filings/0001433660-25-000009.md) | [466](/filings/0001433660-24-000020.md) | [443](/filings/0001433660-24-000035.md) | [473](/filings/0001433660-24-000048.md) | [536](/filings/0001433660-26-000053.md) | [1,183](/filings/0001433660-25-000026.md) | [1,644](/filings/0001433660-25-000045.md) | [1,649](/filings/0001433660-25-000065.md) | [1,622](/filings/0001628280-26-053548.md) | [1,657](/filings/0001628280-26-030756.md) | [1,303](/filings/0001628280-26-053548.md) |
| Long-term debt | $m | [646](/filings/0001433660-23-000041.md) | [646](/filings/0001433660-25-000009.md) | [647](/filings/0001433660-24-000020.md) | [648](/filings/0001433660-24-000035.md) | [648](/filings/0001433660-24-000048.md) | [1,252](/filings/0001433660-26-000053.md) | [1,966](/filings/0001433660-25-000026.md) | [1,511](/filings/0001433660-25-000045.md) | [1,495](/filings/0001433660-25-000065.md) | [1,470](/filings/0001628280-26-053548.md) | [1,432](/filings/0001628280-26-030756.md) | [1,670](/filings/0001628280-26-053548.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001433660-24-000008.md) | not reported | not reported | not reported | [0.0](/filings/0001433660-26-000053.md) | not reported | not reported | [410](/filings/0001433660-25-000065.md) | [412](/filings/0001628280-26-053548.md) | [411](/filings/0001628280-26-030756.md) | [9.0](/filings/0001628280-26-053548.md) |
| Short-term borrowings | $m | [0.0](/filings/0001433660-23-000041.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001433660-26-000053.md) | [21.4](/filings/0001433660-25-000026.md) | [410](/filings/0001433660-25-000045.md) | [411](/filings/0001433660-25-000065.md) | [412](/filings/0001628280-26-053548.md) | [411](/filings/0001628280-26-030756.md) | [9.0](/filings/0001628280-26-053548.md) |
| Shareholders' equity | $m | [1,393](/filings/0001433660-24-000048.md) | [1,489](/filings/0001433660-26-000053.md) | [1,491](/filings/0001433660-25-000045.md) | [1,519](/filings/0001433660-25-000065.md) | [1,585](/filings/0001433660-25-000065.md) | [1,544](/filings/0001628280-26-053548.md) | [4,107](/filings/0001628280-26-053548.md) | [4,374](/filings/0001628280-26-053548.md) | [4,421](/filings/0001433660-25-000065.md) | [4,464](/filings/0001628280-26-053548.md) | [4,483](/filings/0001628280-26-053548.md) | [4,472](/filings/0001628280-26-053548.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [33.0 d](/filings/0001433660-24-000048.md) | [(21.4) d](/filings/0001433660-26-000053.md) | [10.4](/filings/0001433660-25-000026.md) | [21.6 d](/filings/0001433660-25-000045.md) | [71.9 d](/filings/0001433660-25-000065.md) | [129 d](/filings/0001433660-26-000053.md) | [34.0](/filings/0001628280-26-030756.md) | [103 d](/filings/0001628280-26-053548.md) | [87.3 d](/filings/0001433660-25-000065.md) | [117 d](/filings/0001433660-26-000053.md) | [119](/filings/0001628280-26-030756.md) | [102 d](/filings/0001628280-26-053548.md) |
| Capital expenditure | $m | [10.9 d](/filings/0001433660-24-000048.md) | [8.9 d](/filings/0001433660-26-000053.md) | [10.5](/filings/0001433660-25-000026.md) | [10.5 d](/filings/0001433660-25-000045.md) | [6.9 d](/filings/0001433660-25-000065.md) | [10.0 d](/filings/0001433660-26-000053.md) | [20.0](/filings/0001628280-26-030756.md) | [19.0 d](/filings/0001628280-26-053548.md) | [30.7 d](/filings/0001433660-25-000065.md) | [33.9 d](/filings/0001433660-26-000053.md) | [26.0](/filings/0001628280-26-030756.md) | [25.0 d](/filings/0001628280-26-053548.md) |
| Dividends paid | $m | [3.3 d](/filings/0001433660-24-000048.md) | [3.1 d](/filings/0001433660-26-000053.md) | [3.2](/filings/0001433660-25-000026.md) | [3.2 d](/filings/0001433660-25-000045.md) | [3.2 d](/filings/0001433660-25-000065.md) | [3.5 d](/filings/0001433660-26-000053.md) | [5.0](/filings/0001628280-26-030756.md) | [6.0 d](/filings/0001628280-26-053548.md) | [4.7 d](/filings/0001433660-25-000065.md) | [5.2 d](/filings/0001433660-26-000053.md) | [5.0](/filings/0001628280-26-030756.md) | [6.0 d](/filings/0001628280-26-053548.md) |
| Share repurchases | $m | [0.0 d](/filings/0001433660-23-000041.md) | [5.1 d](/filings/0001433660-26-000053.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.1](/filings/0001433660-23-000041.md) | [32.1](/filings/0001433660-24-000020.md) | [32.1](/filings/0001433660-24-000035.md) | [32.2](/filings/0001433660-24-000048.md) | [32.2](/filings/0001433660-25-000026.md) | [32.2](/filings/0001433660-25-000045.md) | [32.2](/filings/0001433660-25-000065.md) | [51.7](/filings/0001628280-26-030756.md) | [52.2](/filings/0001628280-26-053548.md) | [52.3](/filings/0001433660-25-000065.md) | [52.4](/filings/0001628280-26-030756.md) | [52.2](/filings/0001628280-26-053548.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,876,817 at 2026-07-24, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053548.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.